<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-05-15" updated="2020-01-02">
  <drugbank-id primary="true">DB06703</drugbank-id>
  <name>Gadobutrol</name>
  <description>Intravenous gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. It may help visualize and detect vascular abnormalities in the blood brain barrier (BBB) and central nervous system (CNS). &#13;
&#13;
In patients with impaired renal function, gadolinium based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF). A physician should be contacted if symptoms of NSF are encountered, such as dark or red patches on the skin; stiffness in joints; trouble moving, bending or straightening arms, hands, legs or feet; burning, itching, swelling, scaling, hardening and tightening of skin; pain in hip bones or ribs; or muscle weakness. &#13;
&#13;
Common adverse reactions that may be experienced include headache, nausea, feeling hot, abnormal taste, and warmth, burning or pain local to the injection site. &#13;
&#13;
General precautions should be taken in patients who are pregnant or breastfeeding, or who have a history of allergic reaction to contrast media, bronchial asthma or an allergic respiratory disorder.</description>
  <cas-number>770691-21-9</cas-number>
  <unii>1BJ477IO2L</unii>
  <average-mass>604.72</average-mass>
  <monoisotopic-mass>605.13321</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7001</ref-id>
        <pubmed-id>23435930</pubmed-id>
        <citation>Scott LJ: Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig. 2013 Apr;33(4):303-14. doi: 10.1007/s40261-013-0066-0.</citation>
      </article>
      <article>
        <ref-id>A7002</ref-id>
        <pubmed-id>23011188</pubmed-id>
        <citation>Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R: Toxicological safety evaluation of gadobutrol. Invest Radiol. 2012 Nov;47(11):611-23. doi: 10.1097/RLI.0b013e318263f128.</citation>
      </article>
      <article>
        <ref-id>A7003</ref-id>
        <pubmed-id>18821778</pubmed-id>
        <citation>Kunnemeyer J, Terborg L, Nowak S, Scheffer A, Telgmann L, Tokmak F, Gunsel A, Wiesmuller G, Reichelt S, Karst U: Speciation analysis of gadolinium-based MRI contrast agents in blood plasma by hydrophilic interaction chromatography/electrospray mass spectrometry. Anal Chem. 2008 Nov 1;80(21):8163-70. doi: 10.1021/ac801264j. Epub 2008 Sep 27.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Orlin Petrov, Peter Blaszkiewicz, "Process for mono- and 1,7-bis-N-.beta.-hydroxyalkylation of cyclene; N-.beta.-hydroxyalkyl-1,4,7,10-tetraazacyclododecane-lithium-salt complexes and the use of the complexes for the production of gadobutrol and analogs." U.S. Patent US5994536, issued May, 1998.</synthesis-reference>
  <indication>For diagnostic use only. Indicated for adults and children age 2 and over for contrast enhancement during cranial and spinal MRI, and for contrast-enhanced magnetic resonance angiography (CE-MRA). Gadobutrol is particularly suited for the detection of very small lesions and for the visualization of tumors that do not readily take up contrast media. It may be a desired agent when the exclusion or demonstration of an additional pathology may influence the choice of therapy or patient management. It may also be suitable for perfusion studies in the diagnosis of stroke, detection of focal cerebral ischemia, and in studies of tumor perfusion. </indication>
  <pharmacodynamics>Even at low concentrations Gadobutrol can lead to distinct shortening of relaxation times of protons in plasma. At physiological conditions (pH=7, temperature=37°C), and 1.5T, the relaxivity (r1) is 5.2L/(mmol·sec) based on the relaxation times (T1), while the relativity (r2) is 6.1L/(mmol·sec) based on relaxation times (T2). &#13;
&#13;
Magnetic field strength has only slight influence on relaxivities.  &#13;
&#13;
Drug concentration and r1 relaxivity may contribute to a T1 shortening effect, which may improve tissue visualization. </pharmacodynamics>
  <mechanism-of-action>MRI tissue visualization is dependent, in part, on variations in intensity of radiofrequency signals which occur due to differences in proton density, differences of the spin-lattice or longitudinal relaxation times (T1), and differences in the spin-spin or transverse relaxation times (T2).&#13;
&#13;
Gadolinium shortens T1 and T2 relaxation times. Greater signal enhancement is achieved with increased shortening of T1 and T2. The extent to which Gadolinium can shorten T1 and T2 is influenced by concentration in tissue, MRI field strength, and the relative ratio of transverse and longitudinal relaxation times. &#13;
&#13;
The recommended dose produced the greatest sensitivity of T1 shortening effect in T1-weighted magnetic resonance sequences. &#13;
In T2-weighted sequences, the large magnetic moment of gadolinium induced local magnetic field inhomogenenities. &#13;
&#13;
At high concentrations used during bolus injections, T2-weighted sequences show a signal decrease.        </mechanism-of-action>
  <toxicity>Lethality was observed in rodents after a single intravenous administration of 20 mmol/kg. This represents a dose of at least 2 orders of magnitude&#13;
higher than the standard single diagnostic dose in humans (0.1 mmol/kg).&#13;
&#13;
No carcinogenicity studies have been conducted. &#13;
&#13;
No mutagenesis was observed in vitro in reverse mutation tests in bacteria, or in the HGPRT (hypoxanthine-guanine phosphoribosyl transferase) test using Chinese hamster V79 cells. Similarly, no mutagenesis was seen in chromosome abberation tests of human peripheral blood lymphocytes. It was also negative in in-vivo micronucleus tests in mice following a 0.5mmol/kg intravenous injection. &#13;
&#13;
No fertility or reproductive impairment was observed in male and female rates given doses 12.2 times human equivalent doses, based on body surface area.    &#13;
&#13;
Intolerance reactions local to the injection site have been observed in rabbits after paravenous administration, and are associated with the infiltration of inflammatory cells, suggesting the possibility of local irritation if the contrast medium leaks around veins in a clinical setting. </toxicity>
  <metabolism>Gadobutrol is not metabolized. </metabolism>
  <absorption>With normal renal function, the AUC is 1.1 ± 0.1 mmol·h/L. </absorption>
  <half-life>1.81 hours (1.33-2.13 hours). </half-life>
  <protein-binding>No particular protein binding is displayed.</protein-binding>
  <route-of-elimination>Excreted unchanged via glomerular filtration by the kidneys. &#13;
Extrarenal elimination is negligible. </route-of-elimination>
  <volume-of-distribution>Rapid distribution to extracellular space occurs after intravenous administration. &#13;
&#13;
After a dose of 0.1mmol/kg body weight, an average plasma level of 0.59 mmol/L was measured 2 minutes post injection, and 0.3mmol/L 60 minutes post injection.   </volume-of-distribution>
  <clearance>In healthy subjects, renal clearance is 1.1 - 1.7mL/(min·kg).&#13;
Within 2 hours of intravenous injection more than 50% is eliminated via the urine. Within 12 hours more than 90% of the given dose is eliminated. &#13;
&#13;
Clearance was observed to be slightly lower in elderly subjects, when using a 0.1mmol/kg dose. &#13;
&#13;
In the pediatric population, the median AUC, clearance and elimination half life was observed to be similar across the age range of 2-17, based on a population pharmacokinetic analysis of 130 pediatric subjects aged 2-17. In children aged 2-6 (n=45) the median AUC of gadobutrol was 0.8 mmol·h/L, the median clearance was 0.13L/hr/kg, and the median elimination half life was 1.75h. In children aged 7-11 (n=39) the median AUC of gadobutrol was 1.0 mmol·h/L, the median clearance was 0.1L/hr/kg, and the median elimination half life was 1.61h. In children aged 12-17 (n=46) the median AUC of gadobutrol was 1.2 mmol·h/L, the median clearance was 0.09 L/hr/kg, and the median elimination half life was 1.65h. &#13;
Approximately 99% (median value) of the dose was recovered in the urine after 6 hours.  &#13;
&#13;
A prolonged serum half life of gadobutrol is correlated with a reduction in creatinine clearance. In patients with mild-moderate renal impairment (80&gt;CLCR&gt;30 mL/min) the elimination half life was 5.8 ± 2.4 hours, the AUC was 4.0 ± 1.8 mmol·h/L, and complete recovery from the urine is seen within 72 hours. &#13;
In patients with severe renal impairment (CLCR&lt;30 mL/min) the elimination half life was 17.6 ± 6.2 hours, the AUC was 11.5 ± 4.3 mmol·h/L, and complete recovery from the urine is seen within 5 days.        &#13;
Physicians may consider the prompt initiation of hemodialysis following gadobutrol administration to aid elimination, in patients who are already receiving hemodialysis. After one dialysis session 68% of the initial dose is removed, after the second session 94%, and after the third session 98%. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).</description>
    <direct-parent>Alpha amino acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>1,3-aminoalcohols</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid salts</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <alternative-parent>Tricarboxylic acids and derivatives</alternative-parent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>1,3-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteromonocyclic compound</substituent>
    <substituent>Alpha-amino acid</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid salt</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Polyol</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tricarboxylic acid or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english/spanish" coder="inn/usan">Gadobutrol</synonym>
    <synonym language="english" coder="">gadolinium(III) 2,2',2''-(10-((2R,3S )-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Gadavist</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>604.72 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA201277</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gadovist 1.0</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241089</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Gadovist</name>
      <company>Bayer Schering Pharma</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Gadavist</name>
      <ingredients>Gadobutrol</ingredients>
    </mixture>
    <mixture>
      <name>Gadovist 1.0</name>
      <ingredients>Gadobutrol</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Contrast Media</category>
      <mesh-id>D003287</mesh-id>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>Gadolinium-based Contrast Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Magnetic Resonance Contrast Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Magnetic Resonance Imaging Contrast Media</category>
      <mesh-id/>
    </category>
    <category>
      <category>Other Diagnostics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Paramagnetic Contrast Media</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>604.72 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V08CA09">
      <level code="V08CA">Paramagnetic contrast media</level>
      <level code="V08C">MAGNETIC RESONANCE IMAGING CONTRAST MEDIA</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>36:89.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06703.pdf?1367460752</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06703.pdf?1368044731</msds>
  <patents>
    <patent>
      <number>5980864</number>
      <country>United States</country>
      <approved>1999-11-09</approved>
      <expires>2016-11-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Not affected by food.</food-interaction>
  </food-interactions>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.35</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.96e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4,7,10-tris(carboxymethyl)-1-[(2S,3R)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetraaza-13-gadolinatetracyclo[5.5.1.0^{4,13}.0^{10,13}]tridecane-1,4,7,10-tetraium-13-uide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>4,7,10-tris(carboxymethyl)-1-[(2S,3R)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetraaza-13-gadolinatetracyclo[5.5.1.0^{4,13}.0^{10,13}]tridecane-1,4,7,10-tetraium-13-uide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>604.72</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>605.13321</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H31GdN4O9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C18H34N4O9.Gd/c23-12-14(15(25)13-24)22-7-5-20(10-17(28)29)3-1-19(9-16(26)27)2-4-21(6-8-22)11-18(30)31;/h14-15,23-25H,1-13H2,(H,26,27)(H,28,29)(H,30,31);/q;+3/p-3/t14-,15-;/m0./s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ZPDFIIGFYAHNSK-YYLIZZNMSA-K</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>181.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>143.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>45.39</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>0.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11922</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>68841</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>70678987</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99443257</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D07420</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>28533281</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA165958377</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Gadobutrol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2218860</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/gadavist-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/gadavist.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>